JunTop Biosciences

JunTop Biosciences is a clinical-stage biotechnology company based in Suzhou, China, specializing in the research and development of vaccines and anti-infective therapies. As a subsidiary of Junshi Biosciences, the company focuses on addressing significant public health threats, particularly viral infections like COVID-19. Its most advanced program is VV116 (JT001), an oral nucleoside analog targeting the SARS-CoV-2 RNA-dependent RNA polymerase, which has received emergency use authorization in China. JunTop utilizes multiple technology platforms, including recombinant protein and mRNA-based vaccine technologies, to build a diverse pipeline of prophylactic and therapeutic candidates. The company collaborates closely with academic institutions and its parent organization to accelerate the translation of scientific discoveries into clinical solutions.